RxDoctor Payments DataLook up a doctor →

Lauren Downey

Nurse Practitioner · Birmingham, ALNPI 1063075976

Payments from drug & device makers

$19,412in general payments, 2019–2025

Across 910 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Johnson & Johnson$1K
  • Ironwood Pharmaceuticals, Inc$1K
  • Ardelyx, Inc.$1K
  • plus $8K from 36 others

What the payments were for

  • Food & beverage$19,29299%
  • Education$200%
  • Gifts$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,412 in reported general payments places this provider in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$32,299
Medicare patients
224
Services billed
363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide30$32,588
TrulancePlecanatide21$13,620
Colestipol Hcl80$6,187
Dexlansoprazole DrDexlansoprazole15$5,493
ClenpiqSod Picosulf/Mag Ox/Citric Ac29$5,004
Famotidine259$4,685
Esomeprazole Magnesium82$4,469
Lansoprazole111$3,904
Budesonide DrBudesonide20$3,657
Dicyclomine Hcl229$3,369
Pantoprazole Sodium292$3,215
Sucralfate56$1,395
Omeprazole50$840
Ondansetron OdtOndansetron53$803
Hydrocortisone31$597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$3,997$32,58830 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,627$13,62021 claims
Ferring Pharmaceuticals Inc.Clenpiq$112$5,00429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →